Redmile Group, LLC Increases Stake in ALX Oncology Holdings Inc. to 6.8%

Redmile Group, LLC, along with Jeremy C. Green and Redmile Biopharma Investments III, L.P., filed a Schedule 13G/A on May 15, 2026, disclosing a 6.8% stake in ALX Oncology Holdings Inc. (ALXO). As of the event date on March 31, 2026, the reporting persons beneficially owned 9,214,188 shares of common stock. This position includes 7,964,188 shares of common stock and 1,250,000 shares issuable upon the exercise of pre-funded warrants. Specifically, Redmile Biopharma Investments III, L.P. directly holds 4,017,838 shares and the 1,250,000 warrants, representing a 3.9% interest on a standalone basis. Redmile Group, LLC acts as the investment manager for various investment vehicles holding these securities, while Jeremy C. Green serves as the principal of Redmile. The filing indicates an increase in holdings compared to previous reports where the ownership was 0.0%. The reporting persons have shared voting and dispositive power over the disclosed shares and have certified that the acquisition was not intended to influence or change the control of the issuer.